INT356289

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.13
First Reported 2010
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 1
Total Number 4
Disease Relevance 3.02
Pain Relevance 2.52

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Egfr, Egf) endosome (Egfr) cell morphogenesis (Egfr)
intracellular (Egfr) enzyme binding (Egfr) cytoplasm (Egfr)
Anatomy Link Frequency
paw 3
Egfr (Rattus norvegicus)
Egf (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Hyperalgesia 56 100.00 Very High Very High Very High
withdrawal 24 100.00 Very High Very High Very High
agonist 16 100.00 Very High Very High Very High
nociceptor 44 86.64 High High
Pain 52 82.32 Quite High
Inflammation 12 67.92 Quite High
Kinase C 8 5.00 Very Low Very Low Very Low
Analgesic 4 5.00 Very Low Very Low Very Low
Nerve growth factor 4 5.00 Very Low Very Low Very Low
sodium channel 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hyperalgesia 56 100.00 Very High Very High Very High
Wound Healing 12 97.68 Very High Very High Very High
Injury 8 92.64 High High
Nociception 88 86.32 High High
Pain 52 82.32 Quite High
INFLAMMATION 12 67.92 Quite High
Hypersensitivity 4 56.08 Quite High
Starvation 8 46.96 Quite Low
Cancer 8 5.00 Very Low Very Low Very Low
Poisoning 4 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Indeed, as predicted from our cellular studies, intradermal injection of EGF or the physiological relevant EGFR agonist heparine bound EGF (Hb-EGF) led not to an establishment of mechanical hyperalgesia (no significant reduction of paw-withdrawal threshold by 8.5 ± 4.1% (or 3.6 ± 1.9% in other data series) after EGF treatment (n = 6) and 3.0 ± 1,8% after Hb-EGF (n = 12) (Figure 5).


EGFR Binding (bound) of EGF in paw associated with hyperalgesia, agonist and withdrawal
1) Confidence 0.13 Published 2010 Journal Mol Pain Section Body Doc Link PMC3023724 Disease Relevance 0.67 Pain Relevance 0.66
Indeed, as predicted from our cellular studies, intradermal injection of EGF or the physiological relevant EGFR agonist heparine bound EGF (Hb-EGF) led not to an establishment of mechanical hyperalgesia (no significant reduction of paw-withdrawal threshold by 8.5 ± 4.1% (or 3.6 ± 1.9% in other data series) after EGF treatment (n = 6) and 3.0 ± 1,8% after Hb-EGF (n = 12) (Figure 5).


EGFR Binding (bound) of EGF in paw associated with hyperalgesia, agonist and withdrawal
2) Confidence 0.13 Published 2010 Journal Mol Pain Section Body Doc Link PMC3023724 Disease Relevance 0.67 Pain Relevance 0.66
Indeed, as predicted from our cellular studies, intradermal injection of EGF or the physiological relevant EGFR agonist heparine bound EGF (Hb-EGF) led not to an establishment of mechanical hyperalgesia (no significant reduction of paw-withdrawal threshold by 8.5 ± 4.1% (or 3.6 ± 1.9% in other data series) after EGF treatment (n = 6) and 3.0 ± 1,8% after Hb-EGF (n = 12) (Figure 5).


EGFR Neg (not) Binding (bound) of EGF in paw associated with hyperalgesia, agonist and withdrawal
3) Confidence 0.13 Published 2010 Journal Mol Pain Section Body Doc Link PMC3023724 Disease Relevance 0.84 Pain Relevance 0.80
Like NGF, EGF exerts its cellular action via a member of the receptor tyrosine kinase family, the EGFR.
EGFR Binding (via) of EGF
4) Confidence 0.13 Published 2010 Journal Mol Pain Section Body Doc Link PMC3023724 Disease Relevance 0.83 Pain Relevance 0.40

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox